We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

91 hedge funds and large institutions have $40.3M invested in Relmada Therapeutics in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 26 increasing their positions, 33 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

90% more call options, than puts

Call options by funds: $307K | Put options by funds: $162K

4.49% less ownership

Funds ownership: 63.6% → 59.11% (-4.5%)

17% less funds holding

Funds holding: 110 → 91 (-19)

21% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 33

39% less capital invested

Capital invested by funds: $66.6M → $40.3M (-$26.3M)

66% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 29

Holders
91
Holders Change
-19
Holders Change %
-17.27%
% of All Funds
1.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
26
Reduced
33
Closed
29
Calls
$307K
Puts
$162K
Net Calls
+$145K
Net Calls Change
-$5.58M

Top Buyers

1
PAI
Palo Alto Investors
California
+$1.87M
2
Citadel Advisors
Citadel Advisors
Florida
+$1.38M
3
PCM
Parsons Capital Management
Rhode Island
+$779K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$417K
5
GIM
Guild Investment Management
California
+$358K

Top Sellers

1
Millennium Management
Millennium Management
New York
-$2.96M
2
SCM
Sio Capital Management
New York
-$822K
3
Walleye Capital
Walleye Capital
New York
-$728K
4
HF
HRT Financial
New York
-$552K
5
Morgan Stanley
Morgan Stanley
New York
-$486K
Name Holding Trade Value Shares
Change 		Change in
Stake
Squarepoint
101
Squarepoint
New York
– -$123K -35,281 Closed
HS
102
HighVista Strategies
Massachusetts
– -$91.8K -26,299 Closed
GCM
103
Graham Capital Management
Connecticut
– -$91.6K -26,258 Closed
PVI
104
Pura Vida Investments
New York
– -$77.6K -22,233 Closed
Arrowstreet Capital
105
Arrowstreet Capital
Massachusetts
– -$75K -21,420 Closed
QT
106
Quantamental Technologies
New York
– -$54.7K -15,674 Closed
PMEF
107
Point72 Middle East FZE
United Arab Emirates
– -$54.2K -15,517 Closed
CPIG
108
Chicago Partners Investment Group
Illinois
– -$56.5K -14,310 Closed
AC
109
AXQ Capital
New Jersey
– -$43.6K -12,483 Closed
Walleye Trading
110
Walleye Trading
New York
– -$43K -12,334 Closed
ETC
111
Exchange Traded Concepts
Oklahoma
– -$41.8K -11,981 Closed
TWA
112
TCI Wealth Advisors
Arizona
– -$3.76K -1,077 Closed
RTL
113
Red Tortoise LLC
Georgia
– -$1.62K -465 Closed
Nisa Investment Advisors
114
Nisa Investment Advisors
Missouri
– -$1K -400 Closed
Citigroup
115
Citigroup
New York
– -$646 -185 Closed
IA
116
IFP Advisors
Florida
– -$1K -2 Closed
BAM
117
Byrne Asset Management
New Jersey
– -$3 -1 Closed
CS
118
Credit Suisse
Switzerland
– -$3 -1 Closed
FRA
119
Front Row Advisors
California
– +$21 +6 New
1 2 3 4
5

RLMD Hedge Fund Activity: Q1 2023 in Review

91 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q1 2023, worth a combined $40.3M — down 39% from $66.6M a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of RLMD and 10 opened new positions — a net loss of 19 holders — while 33 trimmed existing stakes and 26 added.

The largest buyer was Palo Alto Investors, opening a new position worth an estimated $1.87M. The largest seller was Millennium Management, cutting an estimated $2.96M.

  • 91 institutional investors held Relmada Therapeutics (RLMD) as of Q1 2023, down from 110 in Q4 2022.
  • Funds reported $40.3M of Relmada Therapeutics stock for Q1 2023, down 39% quarter-over-quarter.
  • 10 funds opened new Relmada Therapeutics positions in Q1 2023 and 29 closed out, a net change of -19 holders.
  • The largest Relmada Therapeutics buyer in Q1 2023 was Palo Alto Investors, an estimated $1.87M added.
  • The largest Relmada Therapeutics seller in Q1 2023 was Millennium Management, an estimated $2.96M sold.

Based on aggregated 13F filings for Q1 2023.